"Alternatively activated" dendritic cells preferentially secrete IL-10, expand Foxp3+CD4+ T cells, and induce long-term organ allograft survival in combination with CTLA4-Ig

J Immunol. 2006 Nov 1;177(9):5868-77. doi: 10.4049/jimmunol.177.9.5868.

Abstract

In this study, we propagated myeloid dendritic cells (DC) from BALB/c (H2(d)) mouse bone marrow progenitors in IL-10 and TGF-beta, then stimulated the cells with LPS. These "alternatively activated" (AA) DC expressed lower TLR4 transcripts than LPS-stimulated control DC and were resistant to maturation. They expressed comparatively low levels of surface MHC class II, CD40, CD80, CD86, and programmed death-ligand 2 (B7-DC; CD273), whereas programmed death-ligand 1 (B7-H1; CD274) and inducible costimulatory ligand expression were unaffected. AADC secreted much higher levels of IL-10, but lower levels of IL-12p70 compared with activated control DC. Their poor allogeneic (C57BL/10; B10) T cell stimulatory activity and ability to induce alloantigen-specific, hyporesponsive T cell proliferation was not associated with enhanced T cell apoptosis. Increased IL-10 production was induced in the alloreactive T cell population, wherein CD4+Foxp3+ cells were expanded. The AADC-expanded allogeneic CD4+CD25+ T cells showed enhanced suppressive activity for T cell proliferative responses compared with freshly isolated T regulatory cells. In vivo migration of AADC to secondary lymphoid tissue was not impaired. A single infusion of BALB/c AADC to quiescent B10 recipients induced alloantigen-specific hyporesponsive T cell proliferation and prolonged subsequent heart graft survival. This effect was potentiated markedly by CTLA4-Ig, administered 1 day after the AADC. Transfer of CD4+ T cells from recipients of long-surviving grafts (>100 days) that were infiltrated with CD4+Foxp3+ cells, prolonged the survival of donor-strain hearts in naive recipients. These data enhance insight into the regulatory properties of AADC and demonstrate their therapeutic potential in vascularized organ transplantation.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Abatacept
  • Adoptive Transfer
  • Animals
  • Antigens, CD / analysis
  • Apoptosis
  • CD4 Antigens / analysis
  • Cell Movement
  • Cell Proliferation
  • Combined Modality Therapy
  • Dendritic Cells / drug effects
  • Dendritic Cells / immunology*
  • Dendritic Cells / transplantation*
  • Forkhead Transcription Factors / analysis
  • Graft Rejection / drug therapy
  • Graft Rejection / pathology
  • Graft Rejection / therapy*
  • Graft Survival / immunology*
  • Heart Transplantation* / immunology
  • Heart Transplantation* / pathology
  • Histocompatibility Antigens Class II / analysis
  • Immunoconjugates / administration & dosage*
  • Interleukin-10 / metabolism
  • Interleukin-10 / pharmacology
  • Interleukin-12 / metabolism
  • Lipopolysaccharides / pharmacology
  • Lymphocyte Activation
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Peptides / metabolism
  • Programmed Cell Death 1 Ligand 2 Protein
  • T-Lymphocytes, Regulatory / immunology*
  • Transforming Growth Factor beta / pharmacology

Substances

  • Antigens, CD
  • CD4 Antigens
  • Forkhead Transcription Factors
  • Foxp3 protein, mouse
  • Histocompatibility Antigens Class II
  • Immunoconjugates
  • Lipopolysaccharides
  • Pdcd1lg2 protein, mouse
  • Peptides
  • Programmed Cell Death 1 Ligand 2 Protein
  • Transforming Growth Factor beta
  • Interleukin-10
  • Interleukin-12
  • Abatacept